Cisplatin-Based Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer: Is It Feasible?
Abstract
(ISSN 2638-1311)
OBM Geriatrics is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.7 weeks; Submission to Acceptance: 17.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)
Special Issue
Bladder Cancer in Older Adults
Submission Deadline: July 30, 2021 (Open) Submit Now
Guest Editor
Frank Christoph, MD, PhD, FEBU
Universitätsklinik für Urologie und Kinderurologie, Otto-von-Guericke-Universität, Leipziger Str. 44, 39120 Magdeburg, Germany
Research Interests: Urology surgery; oncology; drug therapy of cancer
About This Topic
Bladder cancer belongs to the five most common cancer types with the majority of patients diagnosed being elderly people between the age of 75 and 84 who account for 30% of new cases per year. Given the fact that demographic prognostics suggest a 3-fold rise of the population aged 80 and over, treating uro-oncologists will face a rising number of patients diagnosed with either non-muscle or muscle invasive bladder cancer.
Therefore, diagnostic approach and therapeutic assessment is a growing matter of debate. It has been suggested that intravesical therapy of superficial bladder cancer can cause higher morbidity and might be less effective. In addition, radical cystectomy in muscle invasive bladder cancer has higher complication and mortality rates as compared to younger patient groups. The renal function is physiologically impaired in elderly patients which might compromise the use of platinum-based chemotherapy.
However, age is relative and various publications have recommended using the term “fit” rather than just “age” in their evaluation of treatment qualification.
Various questions arise if bladder cancer treatment in the elderly is discussed. The most frequent issues which will be content of this editorial are: the role of active surveillance of small superficial tumors, the efficacy of bladder preserving therapy in advanced tumors, the role of chemotherapy or alternatives, the impact of open versus robotic radical cystectomy, and the outcome of continent versus non-continent urinary diversion.
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Publication
Cisplatin-Based Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer: Is It Feasible?by
Clement Dumont
,
Madeleine Lefèvre
,
Quiterie Aussedat
,
Pierre-Louis Régnier
,
Alexandra Masson-Lecomte
,
Evanguelos Xylinas
,
Hélène Gauthier
,
Virginie Fossey-Diaz
,
Amélie Arégui
and
Stéphane Culine
Abstract Cisplatin-based neoadjuvant chemotherapy (C-NAC) has been the standard of care in localized muscle-invasive bladder cancer (MIBC). However, the feasibility and benefit of C-NAC in elderly patients remain uncertain since this population has always been underrepresented in pivotal trials and is often barred from chemotherapy in routi [...] |
TOP